Email bulletin archive

Archive

November 2022

• News from the AASLD Liver Meeting, Washington, DC
• Only 11 countries on target to eliminate hepatitis C by 2030
• Simplified tenofovir regimen as effective as recommended preventive treatment in pregnant women with hepatitis B
• Some people remain at risk for liver cancer after being cured of hepatitis C
• UK community test-and-treat service achieves high hepatitis C cure rate in people who use drugs
• Severe acute hepatitis in children still does not have a definitive cause
• Bepirovirsen treatment leads to sustained loss of hepatitis B markers for up to one in five
• VIR-2218 combined with monoclonal antibody or pegylated interferon delivers potent suppression of hepatitis B

July 2022

• News from the 2022 International Liver Congress
• People cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes
• WHO publishes updated guidance on hepatitis C infection
• Bulevirtide leads to sustained improvement for people with hepatitis D
• Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure
• Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies
• Short-course treatment prevents hepatitis C after organ transplant
• Re-treatment of hepatitis C is highly effective after the first combination fails
• Is this your copy of the infohep news bulletin?

May 2022

• Severe acute hepatitis of unknown cause in children: an update
• UK emergency department screening for viral hepatitis feasible and acceptable
• Ukraine: viral hepatitis and harm reduction services for refugees
• People with diabetes or heavy alcohol consumption at higher risk of severe fibrosis after hepatitis C cure
• Is this your copy of the infohep news bulletin?

April 2022

• Severe acute hepatitis of unknown origin in children
• Sofosbuvir/velpatasvir is suitable for treatment of genotype 4 variants in Africa
• UK report urges re-think on hepatitis C reinfection
• High hepatitis C reinfection rate in prison study highlights harm reduction needs
• Test-and-treat leads to sustained fall in hepatitis C in Swiss gay men with HIV
• Is this your copy of the infohep news bulletin?

March 2022

• COVID-19 pandemic led to a 30% drop in new hepatitis C treatments in the United States
• Accessible care achieves higher hepatitis C cure rate in people who inject drugs
• Depression, anxiety, cognitive performance improve after hepatitis C cure
• Hepatitis C prevalence down by 40% since 2015 in England
• Metabolic disorders cause liver damage in people with HIV more often than viral hepatitis in lower-income countries
• Fatty liver disease raises the risk of cardiovascular disease in people with HIV
• Is this your copy of the infohep news bulletin?

February 2022

• Immunoglobulin-free strategy highly effective for prevention of mother-to-child hepatitis B transmission in Cambodia
• Universal hepatitis C screening in pregnancy improves case detection
• Antihistamine use halved the risk of liver cancer in people with viral hepatitis
• Hepatitis C treatment and cure targets for people living with HIV still not being met in Europe
• New cases of hepatitis C declining in people with HIV as access to treatment broadens
• Is this your copy of the infohep news bulletin?

January 2022

• Some people remain at risk for liver cancer despite hepatitis C treatment
• Bulevirtide for hepatitis D proves effective in real-world studies
• Hepatitis B may increase cancer risk in people with HIV
• One in five new cases of hepatitis C in people who inject drugs due to unstable housing, modelling shows
• Re-infection with hepatitis C has fallen among people with HIV in Europe
• Prioritise harm reduction services to prevent hepatitis C re-infection, Scottish study finds
• Is this your copy of the infohep news bulletin?